星湖科技(600866) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥352,003,207.03, representing a year-on-year increase of 34.43% compared to ¥261,854,216.31 in the same period last year[8]. - Net profit attributable to shareholders for Q3 2022 reached ¥38,810,913.33, a significant increase from ¥-7,298,336.71 in the same period last year, marking an increase of 104.50% year-to-date[8]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥30,388,714.13, up 105.92% from ¥-9,771,788.03 in the same period last year[8]. - Total operating revenue for the first three quarters of 2022 reached ¥982,756,979.74, an increase of 14.3% compared to ¥859,617,648.57 in the same period of 2021[33]. - Net profit for the first three quarters of 2022 was ¥117,248,561.32, compared to ¥57,335,596.98 in 2021, indicating a significant increase of 104.5%[35]. - Basic earnings per share for Q3 2022 were ¥0.0525, up from ¥0.0048 in the same period last year, reflecting a year-to-date increase of 104.51%[8]. - The company reported a basic earnings per share of ¥0.1587, up from ¥0.0776 in the previous year, marking a 104.0% increase[35]. Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥132,178,961.91, a substantial increase of 187.36% compared to ¥45,998,317.29 in the same period last year[8]. - Operating cash inflow for the first three quarters of 2022 reached CNY 905,124,796, an increase of 24.3% compared to CNY 728,339,940 in the same period of 2021[39]. - Cash outflow for purchasing goods and services was CNY 519,894,473.11, up from CNY 393,603,287.43, reflecting a 32.1% increase year-over-year[39]. - The ending balance of cash and cash equivalents increased to CNY 280,999,453.43 from CNY 219,109,783.36, representing a growth of 28.2%[42]. - The company's cash and cash equivalents stood at 280,999,453.43 RMB, compared to 231,033,037.97 RMB at the end of 2021, reflecting a growth of approximately 21.6%[26]. - Total assets at the end of the reporting period were ¥2,505,830,701.27, representing a 2.56% increase from ¥2,473,349,312.72 at the end of the previous year[8]. Shareholder Information - As of the end of the reporting period, the total number of common shareholders was 44,367, with the largest shareholder, Guangdong Guangxin Holdings Group Co., Ltd., holding 149,422,420 shares, representing 20.22% of the total[19]. - Shareholders' equity attributable to the parent company increased to ¥1,863,167,856.87, a rise of 6.73% from ¥1,775,607,578.86 at the end of the previous year[8]. - The total equity attributable to shareholders reached ¥1,863,167,856.87, compared to ¥1,745,617,972.10, an increase of 6.7%[33]. Market and Operational Insights - The increase in revenue was primarily driven by strong market demand for the company's main products, nucleotides and certain raw materials, leading to a rise in both sales volume and price[15]. - The company reported a significant improvement in gross profit due to favorable market conditions, resulting in a strong growth in operating performance[15]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[38]. Liabilities and Expenses - Total liabilities amounted to ¥642,662,844.40, a decrease from ¥697,741,733.86, indicating a reduction of 7.9%[33]. - Non-current liabilities totaled ¥296,726,393.74, up from ¥261,428,086.72, reflecting a growth of 13.5%[33]. - Research and development expenses increased to ¥54,441,204.85 from ¥46,032,373.88, representing a growth of 18.5%[33]. Acquisition Plans - The company is in the process of acquiring 99.22% of Ningxia Yipin Biotechnology Co., Ltd., with the transaction pending approval from the China Securities Regulatory Commission[22]. - The company plans to issue shares to raise funds to support the acquisition, pending regulatory approval, which introduces uncertainty regarding the timing and success of the transaction[22].